State-of-the-art and emerging treatment options in the management of head and neck cancer: News from 2013

Oncology (Switzerland)

Volumn 86, Issue 4, 2014, Pages 212-229

  Denaro, Nerina ^a   Russi, Elvio Grazioso ^a   Adamo, Vincenzo ^b   Merlano, Marco Carlo ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

ASCO and ECC 2013; Chemoradiotherapy; Head and neck cancer; Induction therapy; Multimodal treatment; Organ preservation; Target therapies

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM; ANTINEOPLASTIC AGENT; NEW DRUG;

ADVANCED CANCER; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; EARLY CANCER; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; NECK DISSECTION; NONHUMAN; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; WART VIRUS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); INDUCTION CHEMOTHERAPY; LARYNX; META ANALYSIS (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899771823     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000357712     Document Type: Review

References (106)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Gregoire V, Lefebvre J-L, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v184-v186.
3. Syrjanen S, Lodi G, von Bultzingslowen I, Aliko A, Arduino P, Campisi G, et al: Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011; 17(suppl 1):58-72.
4. Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, et al: Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol 2012; 23: 1832-1837.
5. Chung CH, Gillison ML: Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758-6762.
6. Burtness B, Bauman JE, Galloway T: Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 2013; 14:e302-e309.
7. Haddad RI, Shin DM: Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
8. Lassen P, Overgaard J, Eriksen JG: Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. Radiother Oncol 2013; 108: 489-494.
9. Harrington KJ: From novel insights in molecular biology to targeted treatment approaches in head and neck cancer. EJC Suppl 2013; 11: 275-277.
10. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16. (Pubitemid 30488207)
11. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854. (Pubitemid 44292807)
12. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
13. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, et al: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583-589. (Pubitemid 26139938)
14. Lawrence L: ECC: hyperfractionated radiotherapy improved survival for head and neck cancers. http://www.cancernetwork.com/head-neck-cancer/ecc- hyperfractionatedradiotherapy-improved-survival-head-andneck-cancers.
15. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955. (Pubitemid 30148259)
16. Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol 2009; 92: 4-14.
17. Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, et al: Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009; 10: 341-350.
18. Lassen P: Current role of human papillomavirus in head and neck oncology. EJC Suppl 2013; 11: 260-261.
19. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, et al: ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer 2013; 109: 2096-2105.
20. Salama JK, Seiwert TY, Vokes EE: Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25: 4118-4126. (Pubitemid 47492956)
21. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer ( PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
22. Corvo R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85: 156-170. (Pubitemid 47562578)
23. Canis M, Martin A, Kron M, Konstantinou A, Ihler F, Wolff HA, et al: Results of transoral laser microsurgery in 102 patients with squamous cell carcinoma of the tonsil. Eur Arch Otorhinolaryngol 2013; 270: 2299-2306.
24. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
25. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
26. Benasso M: Induction chemotherapy for squamous cell head and neck cancer: a never ending story? Oral Oncol 2013; 49: 747-752.
27. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704. (Pubitemid 350005151)
28. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715. (Pubitemid 350005152)
29. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer ( PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257-264.
30. Cohen EEW, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2012; 30(suppl):abstr 5500. http://meetinglibrary.asco.org/content/97055- 114.
31. Ma J, Liu Y, Huang X-L, Zhang Z-Y, Myers JN, Neskey DM, et al: Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 2012; 48: 1076-1084.
32. Ghi MG, Paccagnella A, Ferrari D, Foa P: A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): efficacy results (NCT01086826). J Clin Oncol 2013; 31(suppl):abstr 6003 .
33. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol Off J Am Soc Clin Oncol 2013; 31: 853-859.
34. Driessen C, De Boer JP, Gelderblom H, Rasch CRN, Jong M de, Verbist BM, et al: Induction chemotherapy (IC) with docetaxel/cisplatin/5-fluorouracil (TPF) followed by cisplatincontaining concomitant chemoradiotherapy (CRT) in fit patients with locally advanced head and neck cancer (LAHNC): the CONDOR study-a study of the Dutch Head and Neck Society. J Clin Oncol 2013; 31(suppl):abstr 6057. http://meetinglibrary.asco.org/content/112742-132.
35. Driessen CML, De Boer JP, Gelderblom H, Rasch CRN: Efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy followed by two schedules of cisplatin-containing concomitant chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer (LAHNC): the CONDOR study. ECC 2013. Eur J Cancer 2013; 31(suppl):abstr 6057 .
36. Koh Y, Lee K-W, Kim S-B, Park KH, Shin SW, Kang JH, et al: A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). J Clin Oncol 2013; 31(suppl):abstr 6069. http://meetinglibrary.asco.org/content/114425-132.
37. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJC, et al: Taxanecisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013; 31: 2854-2860.
38. Looney WB, Hopkins HA, Carter WH Jr: Solid tumor models for the assessment of different treatment modalities: XXIII-a new approach to the more effective utilization of radiotherapy alternated with chemotherapy. Int J Radiat Oncol Biol Phys 1985; 11: 2105-2117. (Pubitemid 16179983)
39. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, et al: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327: 1115-1121.
40. Corvo R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, et al: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer 2001; 92: 2856-2867.
41. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101: 142-152.
42. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
43. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al: Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31: 845-852.
44. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899. (Pubitemid 26230640)
45. Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al: Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224-228. (Pubitemid 28267175)
46. Gomez-Millan J, Toledo MD, Lupianez Y, Rueda A, Trigo JM, Sachetti A, et al: Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin. Clin Transl Oncol 2013; 15: 321-326.
47. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03.Int J Radiat Oncol Biol Phys 1991; 20: 21-28.
48. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
49. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre J-L, Greiner RH, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952. (Pubitemid 38580197)
50. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005; 27: 843-850. (Pubitemid 41395696)
51. Langendijk JA, Slotman BJ, van der Waal I, Doornaert P, Berkof J, Leemans CR: Riskgroup definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 2005; 104: 1408-1417. (Pubitemid 41356156)
52. Jonkman A, Kaanders JHAM, Terhaard CHJ, Hoebers FJP, van den Ende PLA, Wijers OB, et al: Multicenter validation of recursive partitioning analysis classification for patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 119-125. (Pubitemid 46589828)
53. Denaro N, Russi EG, Adamo V, Colantonio I, Merlano MC: Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. Oncology 2011; 81: 21-29.
54. Denaro N, Russi EG, Numico G, Pazzaia T, Vitiello R, Merlano MC: The role of neck dissection after radical chemoradiation for locally advanced head and neck cancer: should we move back? Oncology 2013; 84: 174-185.
55. Ebrahimi A, Zhang WJ, Gao K, Clark JR: Nodal yield and survival in oral squamous cancer: defining the standard of care. Cancer 2011; 117: 2917-2925.
56. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J: Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12: 418-424. (Pubitemid 14141093)
57. Gillison ML: Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 2006; 24: 5623-5625. (Pubitemid 46631299)
58. Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, et al: Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 2012; 72: 5004-5013.
59. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, et al: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007; 25: 3971-3977. (Pubitemid 47477276)
60. Radiation Therapy Oncology Group: Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. ClinicalTrials.gov Identifier: NCT01302834. RTOG, 2013.
61. De-ESCALaTE HPV: Determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Clinical-Trials.gov Identifier: NCT01874171. 2013. DOI: 10.1186/ISRCTN33522080.
62. Mehra R: Association of XPF and HPV among squamous cell head and neck cancer tumors: biomarker analysis of ECOG 3303. The European Cancer Congress 2013, abstract No. 3152.
63. Price KAR, Cohen EE: Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012; 13: 35-46.
64. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672. (Pubitemid 46622088)
65. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
66. Buntzel J, Micke O: Second-line chemotherapy in head and neck cancer: what should we expect? Expert Rev Anticancer Ther 2009; 9: 269-273.
67. Jimenez B, Trigo JM, Pajares BI, Saez MI, Quero C, Navarro V, et al: Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol 2013; 49: 182-185.
68. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia-Saenz JA, Cruz-Hernandez JJ, et al: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23: 1016-1022.
69. Sosa AE, Grau JJ, et al: Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy. Eur Arch Otorhinolaryngol 2014; 271: 373-378.
70. Patil V , Noronha V , Joshi A, et al : Is gemcitabine and nimotuzumab (Nim-Gem) an option post-cetuximab-based chemotherapy failure in head and neck cancers? European Cancer Congress 2013; abstract 3237 P332.
71. De Andrade DAP, Machiels J-P: Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr Opin Oncol 2012; 24: 211-217.
72. Vermorken JB, Licitra L, Stohlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, et al: Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 2013; 49: 2877-2883.
73. Adkins D, Ley J, Trinkaus K, Thorstad W, Lewis J Jr, Wildes T, et al: A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer 2013; 119: 766-773.
74. Fury MG, Sherman EJ, Rao SS, Wolden SL, Smith-Marrone S, Ng KK, et al: Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensitymodulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2013; 31(suppl):abstr 6034. http://meeting library.asco.org/content/110307-132.
75. Loong HH, Hope A, Winquist E, Hammond A, et al: Phase I trial of nab-paclitaxel (A), cisplatin (P) and 5-fluorouracil (F) induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in patients (pts) with locoregionally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final results. Eur J Cancer 2013; 49:S749.
76. Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, et al: Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist 2013; 18: 850-864.
77. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14: 697-710.
78. Wirth LJ, Dakhil SR, Kornek G, Axelrod R, Adkins D, Pant S, et al: PARTNER: a randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013; 31(suppl):abstr 6029. http://meetinglibrary.asco.org/ content/117040-132.
79. Giralt J, Fortin A, Mesia R, Minn H, Henke M, Ancona AY, et al: A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012; 30:abstr 5502. http ://meeting library.as co. org/content/93724-114.
80. Giralt J, Trigo JM, Nuyts S, Ozsahin EM, Skladowski K, et al: Phase 2, randomized trial (CONCERT-2) of panitumumab (PMAB) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Ann Onc 2012; 23(suppl 10) :Ix334-Ix347.
81. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011; 29(suppl); abstr 5500. http://meetinglibrary.asco.org/content/79086-102.
82. Psyrri A, Seiwert TY, Jimeno A: Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book 2013; 246-255.
83. Somani N, Karandikar SM, Bokil K, Bhowmik KT, Agarwal S, et al: Nimotuzumab with concurrent chemoradiotherapy in patients with locally advanced head and neck cancer ( LASCCHN). J Clin Oncol 2013; 31(suppl):abstr 6084. http://meetinglibrary.asco.org/content/116686-132.
84. Machiels J-P, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, et al: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinumbased chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12: 333-343.
85. Eriksen JG, Maare C, Johansen J, Primdahl H, et al: DAHANCA 19: first results of a randomized phase III study of the importance of the EGFR-inhibitor zalutumumab for the outcome of primary curative radiotherapy for squamous cell carcinoma of the head and neck. Poster Presentation, ESTRO ECC, Amsterdam, 2013.
86. Argiris A, Ghebremichael M, Gilbert J, Lee J-W, Sachidanandam K, Kolesar JM, et al: Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2013; 31: 1405-1414.
87. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013; 31: 1415-1421.
88. Herchenhorn D, Dias FL, Viegas CMP, Federico MH, Araujo CMM, Small I, et al: Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 78: 696-702.
89. Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, et al: Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virusnegative disease. Eur J Cancer Oxf Engl 1990 2013; 49: 1609-1618.
90. De Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, et al: A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18: 2336-2343.
91. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, et al: Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2012; 48: 887-892.
92. Denaro N, Russi EG, Colantonio I, Adamo V, Merlano MC: The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology 2012; 83: 108-116.
93. Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, et al: A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer 2012; 131: 956-969.
94. Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, et al: A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 2013; 119: 1823-1831.
95. Raymond E, Tourneau CL, Gatineau M, Delord J-P, Fayette J, Dreyer C, et al: CAPRA: safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2013; 31(suppl):abstr 6036. http://meetinglibrary. asco.org/content/117144-132.
96. Fury MG, Sherman E, Ho A, Katabi N, Sima C, Kelly KW, et al: A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer ( HNSCC). Cancer Chemother Pharmacol 2012; 70: 121-128.
97. Grunwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B: Temsirolimus is active in refractory squamous cell carcinoma of the head and neck (SCCHN) failing platinum-based chemotherapy and cetuximab: efficacy and toxicity data from the phase II temhead study. Ann Oncol 2012; 23:ix334-ix347 .
98. Bauman JE, Arias-Pulido H, Lee S-J, Fekrazad MH, Ozawa H, Fertig E, et al: A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 2013; 49: 461-467.
99. Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ: Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther 2012; 12: 1669-1678.
100. Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, et al: Impact of age on acute toxicity induced by bioor chemo-radiotherapy in patients with head and neck cancer. Oral Oncol 2012; 48: 1051-1057.
101. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
102. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506.
103. Prades J-M, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, et al: Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol (Stockh) 2010; 130: 150-155.
104. Budach W, Hehr T, Budach V, Belka C, Dietz K: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;31:6-28.
105. Machiels J-PH, Specenier PM, Krauss J, Dietz A, Kaminsky M-C, Lalami Y, et al: Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study. J Clin Oncol 2013;31(suppl):abstr 6002.
106. Cupissol D, Seiwert TY, Fayette J, Ehrnrooth E, Blackman AS, Cong XJ, Cohen EEW: A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover. J Clin Oncol 2013;31(suppl):abstr 6001.